Introduction

AML1-ETO is the most common chromosomal aberration in de novo acute myeloid leukemia (AML) patients. This abnormality is resulted from t(8;21)(q22;q22) translocation. The translocation, produces a fusion protein which inhibits myeloid transcriptional factors and as a result, cellular differentiation is blocked. This alteration occurs in approximately 7% of adult and 12% of pediatric with AML.

AML1-ETO RQ provides a ready-to-use system for detection and quantitation of AML1-ETO transcripts as well as calculation of AML1-ETO percentage.